The EU has given Gilead the green light to market its twice-yearly pre-exposure prophylaxis (PrEP) product lenacapavir, which ...

Analysts and charities have identified Gilead’s new HIV prevention injection as key to curbing infection rates ...

Gilead Sciences (NASDAQ:GILD) announced on Tuesday that the European Commission granted marketing authorization for its ...

As global leaders convene for the G20 summit in South Africa, the spotlight is on fortifying health systems through ...